Loading…
Sonida Senior Living, Inc. owns and operates senior housing communities in the United States. The company provides independent living services, which include daily meals, transportation, social and recreational activities, laundry, housekeeping, and 24-hour staffing; and access to health screenings, periodic special services, and dietary and similar programs, as well as exercise and fitness classes. It offers assisted living services consist of personal care services, such as assistance with activities of daily living, including ambulation, bathing, dressing, eating, grooming, personal hygiene, and monitoring or assistance with medications; support services, such as meals, assistance with social and recreational activities, laundry, general housekeeping, maintenance, and transportation services; and supplemental services, which include extra transportation, personal maintenance, and extra laundry services, as well as special care services for residents with various forms of dementia. In addition, it offers memory care services; and home care services through third-party providers, such as customized physician, dentistry, podiatry, and other health-related rehabilitation and therapy services. Further, it provides respite care and temporary care and therapy programs. The company was formerly known as Capital Senior Living Corporation and changed its name to Sonida Senior Living, Inc. in November 2021. Sonida Senior Living, Inc. was founded in 1990 and is based in Dallas, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $381M | $23M | $-71M | $-9M | -125.8% | 25.2% | - |
| 2024 | $304M | $78M | $-2M | $-27M | -1.6% | 19.2% | - |
| 2023 | $255M | $55M | $-21M | $-7M | 31.7% | 7.1% | - |
| 2022 | $238M | $17M | $-54M | $-27M | 93.5% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 238.43 | 255.32 | 304.33 | 381.14 |
| Cost Of Revenue | 27.37 | 21.10 | 33.10 | 44.75 |
| Gross Profit | 211.06 | 234.22 | 271.23 | 336.39 |
| Operating Expense | 240.37 | 249.41 | 280.19 | 349.84 |
| Operating Income | -29.31 | -15.19 | -8.96 | -13.45 |
| EBITDA | 17.16 | 55.15 | 78 | 23.24 |
| EBIT | -21.29 | 15.26 | 33.95 | -33.53 |
| Pretax Income | -54.31 | -20.85 | -3.04 | -72.16 |
| Tax Provision | 0.09 | 0.25 | 0.24 | 0.33 |
| Net Income | -54.40 | -21.11 | -2.06 | -70.78 |
| Net Income Common Stockholders | -58.97 | -26.10 | -7.58 | -76.42 |
| Total Expenses | 267.74 | 270.51 | 313.29 | 394.59 |
| Interest Expense | 33.02 | 36.12 | 36.99 | 38.63 |
| Interest Income | 0.23 | 0.61 | 1.68 | 2.10 |
| Selling General And Administration | 30.29 | 32.20 | 34.12 | 39.85 |
| Normalized EBITDA | 19.39 | 24.78 | 35.34 | 52 |
| Normalized Income | -52.64 | -45.10 | -35.76 | -48.06 |
| Basic EPS | -9.27 | -3.85 | -0.54 | 0 |
| Diluted EPS | -9.27 | -3.85 | -0.54 | 0 |
| Tax Effect Of Unusual Items | -0.47 | 6.38 | 8.96 | -6.04 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.21 | 0.21 |
| Total Unusual Items | -2.23 | 30.37 | 42.66 | -28.76 |
| Total Unusual Items Excluding Goodwill | -2.23 | 30.37 | 42.66 | -28.76 |
| Net Income From Continuing Operation Net Minority Interest | -54.40 | -21.11 | -2.06 | -70.78 |
| Reconciled Depreciation | 38.45 | 39.89 | 44.05 | 56.77 |
| Reconciled Cost Of Revenue | 27.37 | 21.10 | 33.10 | 44.75 |
| Net Interest Income | -32.79 | -35.51 | -35.31 | -36.53 |
| Net Income From Continuing And Discontinued Operation | -54.40 | -21.11 | -2.06 | -70.78 |
| Rent Expense Supplemental | 0 | 0 | 0 | 0 |
| Diluted Average Shares | 6.36 | 6.79 | 14.11 | 0 |
| Basic Average Shares | 6.36 | 6.79 | 14.11 | 0 |
| Diluted NI Availto Com Stockholders | -58.97 | -26.10 | -7.58 | -76.42 |
| Otherunder Preferred Stock Dividend | 0 | 0 | 0 | 0 |
| Preferred Stock Dividends | 4.57 | 4.99 | 5.53 | 5.64 |
| Minority Interests | 0 | 0 | 1.22 | 1.71 |
| Net Income Including Noncontrolling Interests | -54.40 | -21.11 | -3.28 | -72.49 |
| Net Income Continuous Operations | -54.40 | -21.11 | -3.28 | -72.49 |
| Other Income Expense | 7.78 | 29.84 | 41.23 | -22.18 |
| Other Non Operating Income Expenses | 10.01 | -0.53 | -0.54 | 7.95 |
| Special Income Charges | -2.23 | 30.37 | 42.66 | -28.76 |
| Gain On Sale Of Ppe | 0 | 0 | 0 | 0 |
| Other Special Charges | 0.64 | -36.34 | -48.54 | 0 |
| Write Off | 0 | 0 | 0 | 0 |
| Impairment Of Capital Assets | 1.59 | 5.96 | 0 | 12.53 |
| Restructuring And Mergern Acquisition | 0 | 0 | 5.87 | 16.23 |
| Earnings From Equity Interest | 0 | 0 | -0.90 | -1.37 |
| Net Non Operating Interest Income Expense | -32.79 | -35.51 | -35.31 | -36.53 |
| Interest Expense Non Operating | 33.02 | 36.12 | 36.99 | 38.63 |
| Interest Income Non Operating | 0.23 | 0.61 | 1.68 | 2.10 |
| Other Operating Expenses | 171.63 | 177.32 | 202.01 | 253.22 |
| Depreciation Amortization Depletion Income Statement | 38.45 | 39.89 | 44.05 | 56.77 |
| Depreciation And Amortization In Income Statement | 38.45 | 39.89 | 44.05 | 56.77 |
| General And Administrative Expense | 30.29 | 32.20 | 34.12 | 39.85 |
| Other Gand A | 30.29 | 32.20 | 34.12 | 39.85 |
| Rent And Landing Fees | 0 | 0 | 0 | 0 |
| Salaries And Wages | 0 | 0 | 0 | 0 |
| Operating Revenue | 238.43 | 255.32 | 304.33 | 381.14 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Sonida Senior Living, Inc.this co. | SNDA | $1.8B | - | -37500.00 | -125.8% | 57.41 |
| Syndax Pharmaceuticals, Inc. | SNDX | $1.8B | - | 27.92 | -441.6% | -6.40 |
| Surgery Partners, Inc. | SGRY | $1.8B | - | 1.04 | -2.2% | 11.28 |
| AnaptysBio, Inc. | ANAB | $1.8B | - | 46.94 | -35.6% | 36.55 |
| Taysha Gene Therapies, Inc. | TSHA | $1.8B |
| - |
| 7.24 |
| -44.1% |
| -14.19 |
| Harmony Biosciences Holdings, Inc. | HRMY | $1.8B | 11.23 | 2.05 | 18.2% | 4.68 |
| Palvella Therapeutics, Inc. | PVLA | $1.8B | - | 54.18 | -149.1% | - |
| Recursion Pharmaceuticals, Inc. | RXRX | $1.7B | - | 1.54 | -57.0% | -1.91 |
| Amylyx Pharmaceuticals, Inc. | AMLX | $1.7B | - | 5.62 | -47.4% | -9.25 |
| Peer Median | - | 11.23 | 6.43 | -45.8% | -1.91 | |